Clinical trials · Philadelphia, PA
Liver Diseases clinical trials in Philadelphia
We’re tracking 16 recruiting liver diseases studies with a site in or near Philadelphia — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Philadelphia, PennsylvaniaAges 18–75 - NCT05733832Recruiting
Transitional care after hospital discharge for serious liver disease
This trial tests an extra support program after you leave the hospital to help people with advanced liver disease avoid complications and stay on track. It may help by providing structured follow-up soon after discharge.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07165028RecruitingPhase 3
Study of new drugs for fatty liver with scarring
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04181138Recruiting
Study of childhood primary sclerosing cholangitis types
This study follows children and young adults with primary sclerosing cholangitis (PSC) to understand the condition and how it shows up on scans or biopsy. It may help doctors better recognize PSC and choose the best next steps for care.
Philadelphia, PennsylvaniaAges 2–25 - NCT05744713Enrolling by invitation
Study of adults with long-term liver disease using health records
This observational study looks at adults with chronic liver disease (including cirrhosis) to better understand how people are managed and how they feel over time. Because it does not change your treatment, it may help researchers improve care and patient support.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05470205RecruitingPhase 3
Noninvasive blood-pressure measurement to estimate liver portal pressure
This Phase 3 study tests a noninvasive ultrasound-based method to estimate portal hypertension, which is high blood pressure in the liver’s blood vessels. It aims to help doctors measure how severe the liver circulation problem is without needing invasive pressure testing.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Philadelphia, PennsylvaniaAges 18–70 - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
Philadelphia, PennsylvaniaAges 3–13 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Philadelphia, PennsylvaniaAges 18–75 - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00345930Recruiting
Study of liver injury after medicines or supplements
This study looks at people (including children over age 2) who develop liver injury that may be caused by a drug or a complementary/alternative medicine (CAM) product. It helps doctors better understand what causes the injury and how to evaluate it.
Philadelphia, PennsylvaniaAges 2 years+ - NCT04613921Recruiting
Liver transplant study for severe worsening liver failure
This study looks at when liver transplant is offered and what outcomes happen in people with cirrhosis who have severe “acute-on-chronic” worsening. It may help doctors decide which patients benefit most from transplant and improve care after listing or not listing.
Philadelphia, PennsylvaniaAges 18–80 - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Flourtown, PennsylvaniaAges 18 years+ - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Flourtown, PennsylvaniaAges 18 years+
Hear when a new Liver Diseases trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Liver Diseases trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting liver diseases studies listed above.
- University of Pennsylvania · 7 studies
- US Digestive Health · 3 studies
- Children's Hospital of Philadelphia · 2 studies
- Temple University Hospital · 2 studies
- Thomas Jefferson University Hospital · 2 studies
- Clinical Research of Philadelphia
- Einstein Medical Center Philadelphia
- GSK Investigational Site
What taking part in a liver diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting liver diseases studies in Pennsylvania.
Common questions
- Are there liver diseases clinical trials near Philadelphia?
- Yes. We're currently tracking 16 recruiting liver diseases studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a liver diseases study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a liver diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New liver diseases studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.